Mycogynax Dosage

Rating: 2.5 - 2 review(s)
sponsored
How old is patient?

Consists of Chloramphenicol, Dexamethasone, Metronidazole, Nystatin

Dosage of Chloramphenicol (Mycogynax) in details

infoThe dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.
sponsored

Chloramphenicol (Mycogynax), like other potent drugs, should be prescribed at recommended doses known to have therapeutic activity. Administration of 50 mg/kg/day in divided doses will produce blood levels of the magnitude to which the majority of susceptible microorganisms will respond.

As soon as feasible an oral dosage form of another appropriate antibiotic should be substituted for intravenous Chloramphenicol (Mycogynax) sodium succinate.

The following method of administration is recommended:

Intravenously as a 10% (100 mg/mL) solution to be injected over at least a one-minute interval. This is prepared by the addition of 10 mL of an aqueous diluent such as water for injection or 5% dextrose injection.

Adults

Adults should receive 50 mg/kg/day in divided doses at 6-hour intervals. In exceptional cases patients with infections due to moderately resistant organisms may require increased dosage up to 100 mg/kg/day to achieve blood levels inhibiting the pathogen, but these high doses should be decreased as soon as possible. Adults with impairment of hepatic or renal function or both may have reduced ability to metabolize and excrete the drug. In instances of impaired metabolic processes, dosages should be adjusted accordingly. Precise control of concentration of the drug in the blood should be carefully followed in patients with impaired metabolic processes by the available microtechniques (information available on request).

Pediatric Patients

Dosage of 50 mg/kg/day divided into 4 doses at 6-hour intervals yields blood levels in the range effective against most susceptible organisms. Severe infections (eg, bacteremia or meningitis), especially when adequate cerebrospinal fluid concentrations are desired, may require dosage up to 100 mg/kg/day; however, it is recommended that dosage be reduced to 50 mg/kg/day as soon as possible. Children with impaired liver or kidney function may retain excessive amounts of the drug.

Neonates

A total of 25 mg/kg/day in 4 equal doses at 6-hour intervals usually produces and maintains concentrations in blood and tissues adequate to control most infections for which the drug is indicated. Increased dosage in these individuals, demanded by severe infections, should be given only to maintain the blood concentration within a therapeutically effective range. After the first two weeks of life, full-term neonates ordinarily may receive up to a total of 50 mg/kg/day equally divided into 4 doses at 6-hour intervals. These dosage recommendations are extremely important because blood concentration in all premature and full-term neonates under two weeks of age differs from that of other infants neonates. This difference is due to variations in the maturity of the metabolic functions of the liver and the kidneys.

When these functions are immature (or seriously impaired in adults), high concentrations of the drug are found which tend to increase with succeeding doses.

Pediatric Patients with Immature Metabolic Processes

In young infants and other pediatric patients in whom immature metabolic functions are suspected, a dose of 25 mg/kg/day will usually produce therapeutic concentrations of the drug in the blood. In this group particularly, the concentration of the drug in the blood should be carefully followed by microtechniques. (Information available on request.)

Chloramphenicol (Mycogynax) interactions

infoInteractions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Chloramphenicol (Mycogynax), it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.
sponsored

There are no known drug interactions arising from the use of topical medication. Vitamin E administered systemically can increase the pharmacological action of insulin and digital. The absorption and accumulation of vitamin A can be reduced respectively by Neomycin sulphate some drugs such corticosteroids administered for prolonged periods, phenobarbital, caffeine and alcohol. And ’demonstrated a significant relationship between vitamin D and phenytoin or phenobarbital.

Among patients treated with these drugs for a long time, it is noted a high incidence of rickets and osteomalacia. Chloramphenicol (Mycogynax) irreversibly inhibits the enzymes of hepatic microsomal cytochrome P450 complex and this may result in a longer half-lives of drugs metabolized by this system (dicoumarol, phenytoin, chlorpropamide and tolbutamide). Chronic administration of phenobarbital or acute administration of rifampicin shorten the half-lives of Chloramphenicol (Mycogynax) and subsequent formation of sub-therapeutic concentrations of the drug.

Dosage of Dexamethasone (Mycogynax) in details

infoThe dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.
sponsored

Dexamethasone (Mycogynax) Dosage

Generic name: Dexamethasone (Mycogynax) 1.5mg

Dosage form: tablet

Medically reviewed on August 16, 2017.

For oral administration: The initial dosage of Dexamethasone (Mycogynax) varies from 0.75 to 9 mg a day depending on the disease being treated.

It Should Be Emphasized That Dosage Requirements Are Variable And Must Be Individualized On The Basis Of The Disease Under Treatment And The Response Of The Patient.

After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage that maintains an adequate clinical response is reached.

Situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patients individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of the corticosteroid for a period of time consistent with the patients condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.

In the treatment of acute exacerbations of multiple sclerosis, daily doses of 30 mg of Dexamethasone (Mycogynax) for a week followed by 4 to 12 mg every other day for one month have been shown to be effective. In pediatric patients, the initial dose of Dexamethasone (Mycogynax) may vary depending on the specific disease entity being treated. The range of initial doses is 0.02 to 0.3 mg/kg/day in three or four divided doses (0.6 to 9 mg/m2body surface area/day).

For the purpose of comparison, the following is the equivalent milligram dosage of the various corticosteroids:

Dexamethasone (Mycogynax), 1.5 Methylprednisolone, 8
Predisone, 10 Triamcinolone, 8
Prednisolone, 10 Betamethasone, 1.5
Hydrocortisone, 40 Paramethasone, 4
Cortisone, 50

These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered.

In acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders, the following dosage schedule combining parenteral and oral therapy is suggested: Dexamethasone (Mycogynax) Sodium Phosphate injection, USP 4 mg per mL:

First Day

1 or 2 mL, intramuscularly

Dexamethasone (Mycogynax) Tablets, USP, 1.5 mg, one-half tablet:

Second Day

2 tablets in two divided doses

Third Day

2 tablets in two divided doses

Fourth Day

1 tablet in two divided doses

Fifth Day

One half tablet

Sixth Day

One half tablet

Seventh Day

No treatment

Eighth Day

Follow-up visit

This schedule is designed to ensure adequate therapy during acute episodes, while minimizing the risk of overdosage in chronic cases.

In cerebral edema, Dexamethasone (Mycogynax) Sodium Phosphate injection, USP is generally administered initially in a dosage of 10 mg intravenously followed by 4 mg every six hours intramuscularly until the symptoms of cerebral edema subside. Response is usually noted within 12 to 24 hours and dosage may be reduced after two to four days and gradually discontinued over a period of five to seven days. For palliative management of patients with recurrent or inoperable brain tumors, maintenance therapy with either Dexamethasone (Mycogynax) Sodium Phosphate injection, USP or Dexamethasone (Mycogynax) tablets in a dosage of 2 mg two or three times daily may be effective.

Dexamethasone (Mycogynax) suppression tests:

1. Tests for Cushing’s syndrome.

Give 1 mg of Dexamethasone (Mycogynax) USP orally at 11:00 p.m. Blood is drawn for plasma cortisol determination at 8:00 a.m. the following morning. For greater accuracy, give 0.5 mg of Dexamethasone (Mycogynax) USP orally every 6 hours for 48 hours. Twenty-four hour urine collections are made for determination of 17-hydroxycorticosteroid excretion.

2. Test to distinguish Cushing’s syndrome due to pituitary AGTH excess from Cushing’s syndrome due to other causes.

Give 2 mg of Dexamethasone (Mycogynax) USP orally every 6 hours for 48 hours. Twenty-four hour urine collections are made for determination of 17-hydroxycorticosteroid excretion.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

More about Dexamethasone (Mycogynax) (Dexamethasone (Mycogynax))

  • Dexamethasone (Mycogynax) Side Effects
  • During Pregnancy or Breastfeeding
  • Drug Images
  • Drug Interactions
  • Drug class: glucocorticoids

Consumer resources

  • Dexamethasone (Mycogynax)

Other brands: Decadron, Dexamethasone (Mycogynax) Intensol, Dexasone, Dexacen-4,... +7 more

Professional resources

  • Dexamethasone (Mycogynax) (FDA)
  • Dexamethasone (Mycogynax) sodium phosphate (AHFS Monograph)

Related treatment guides

  • Addison's Disease
  • Adrenal Insufficiency
  • Adrenogenital Syndrome
  • Allergic Rhinitis
  • ... +8 more

What other drugs will affect Dexamethasone (Mycogynax)?

Many drugs can interact with Dexamethasone (Mycogynax). Below is just a partial list. Tell your doctor if you are using:

  • aspirin (taken on a daily basis or at high doses);

  • a diuretic (water pill);

  • a blood thinner such as warfarin (Coumadin);

  • cyclosporine (Gengraf, Neoral, Sandimmune);

  • insulin or diabetes medications you take by mouth;

  • ketoconazole (Nizoral);

  • rifampin (Rifadin, Rifater, Rifamate, Rimactane); or

  • seizure medications such as phenytoin (Dilantin) or phenobarbital (Luminal, Solfoton).

This list is not complete and other drugs may interact with Dexamethasone (Mycogynax). Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Dexamethasone (Mycogynax) interactions

infoInteractions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Dexamethasone (Mycogynax), it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.
sponsored

Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids.

Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.

Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.

Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.

Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect.

Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.

Antitubercular drugs: Serum concentrations of isoniazid may be decreased. Cholestyramine: Cholestyramine may increase the clearance of corticosteroids. Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use.

Dexamethasone (Mycogynax) suppression test (DST): False-negative results in the Dexamethasone (Mycogynax) suppression test (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients.

Digitalis glycosides: Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.

Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.

Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids. Dexamethasone (Mycogynax) is a moderate inducer of CYP 3A4. Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., indinavir, erythromycin) may increase their clearance, resulting in decreased plasma concentration.

Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects. In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.

Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids.

Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with Dexamethasone (Mycogynax) co-administration, leading to alterations in seizure control.

Skin tests: Corticosteroids may suppress reactions to skin tests.

Thalidomide: Co-administration with thalidomide should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use.

Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.

Dosage of Metronidazole (Mycogynax) in details

infoThe dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.

In elderly patients the pharmacokinetics of Metronidazole (Mycogynax) may be altered and therefore monitoring of serum levels may be necessary to adjust the Metronidazole (Mycogynax) dosage accordingly.

Treatment of Anaerobic Infections

The recommended dosage schedule for adults is:

Loading Dose 15 mg/kg infused over one hour (approximately 1 g for a 70-kg adult).
Maintenance Dose 7.5 mg/kg infused over one hour every six hours (approximately 500 mg for a 70-kg adult). The first maintenance dose should be instituted six hours following the initiation of the loading dose.

Parenteral therapy may be changed to oral Metronidazole (Mycogynax) when conditions warrant, based upon the severity of the disease and the response of the patient to Metronidazole (Mycogynax) Injection, USP RTU treatment. The usual adult oral dosage is 7.5 mg/kg every six hours.

A maximum of 4 g should not be exceeded during a 24-hour period.

Patients with severe hepatic disease metabolize Metronidazole (Mycogynax) slowly, with resultant accumulation of Metronidazole (Mycogynax) and its metabolites in the plasma. Accordingly, for such patients, doses below those usually recommended should be administered cautiously. Close monitoring of plasma Metronidazole (Mycogynax) levels and toxicity is recommended.

In patients receiving Metronidazole (Mycogynax) Injection, USP RTU in whom gastric secretions are continuously removed by nasogastric aspiration, sufficient Metronidazole (Mycogynax) may be removed in the aspirate to cause a reduction in serum levels.

The dose of Metronidazole (Mycogynax) Injection, USP RTU should not be specifically reduced in anuric patients since accumulated metabolites may be rapidly removed by dialysis.

The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract and endocardium may require longer treatment.

Prophylaxis

For surgical prophylactic use, to prevent postoperative infection in contaminated or potentially contaminated colorectal surgery, the recommended dosage schedule for adults is:

  1. 15 mg/kg infused over 30 to 60 minutes and completed approximately one hour before surgery; followed by
  2. 7.5 mg/kg infused over 30 to 60 minutes at 6 and 12 hours after the initial dose.

It is important that (1) administration of the initial preoperative dose be completed approximately one hour before surgery so that adequate drug levels are present in the serum and tissues at the time of initial incision, and (2) Metronidazole (Mycogynax) Injection, USP RTU be administered, if necessary, at 6-hour intervals to maintain effective drug levels. Prophylactic use of Metronidazole (Mycogynax) Injection, USP RTU should be limited to the day of surgery only, following the above guidelines.

Caution: Metronidazole (Mycogynax) Injection, USP RTU is to be administered by slow intravenous drip infusion only, either as a continuous or intermittent infusion. Additives should not be introduced into Metronidazole (Mycogynax) Injection, USP RTU. If used with a primary intravenous fluid system, the primary solution should be discontinued during Metronidazole (Mycogynax) infusion. DO NOT USE EQUIPMENT CONTAINING ALUMINUM (e.g., NEEDLES, CANNULAE) THAT WOULD COME IN CONTACT WITH THE DRUG SOLUTION.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

How supplied

Metronidazole (Mycogynax) Injection, USP RTU is supplied in 100 mL single dose plastic containers, each containing an iso-osmotic, buffered solution of 500 mg Metronidazole (Mycogynax) as follows:

2B3421 -NDC 0338-1055-48 -500 mg/100 mL

Store at controlled room temperature, 59° to 86°F (15° to 30°C) and protect from light during storage. Do not remove unit from overwrap until ready for use. The overwrap is a moisture barrier. The inner bag maintains the sterility of the product. After removing overwrap, check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired.

Directions For Use Of Viaflex Plus Plastic Container

Metronidazole (Mycogynax) Injection, USP RTU is a ready-to-use iso-osmotic solution. No dilution or buffering is required. Do not refrigerate. Each container of Metronidazole (Mycogynax) Injection, USP RTU contains 14 mEq of sodium.

Warning: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.

To open

Tear overwrap down side at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for leaks. Do not add supplementary medication.

Preparation for Administration
  1. Suspend container from eyelet support.
  2. Remove protector from outlet port at bottom of container.
  3. Attach administration set. Refer to complete directions accompanying set.

REFERENCES

3. Ralph, E.D. and Kirby, W.M.M.: Bioassay of Metronidazole (Mycogynax) with Either Anaerobic and Aerobic Incubation, J. Infect. Dis. 132:587-591 (Nov.) 1975; or Gulaid, et al.: Determination of Metronidazole (Mycogynax) and its Major Metabolites in Biological Fluids by High Pressure Liquid Chromatography. BR.J.Clin. Pharmacol. 6:430-432, 1978.

Baxter Healthcare Corporation, Deerfield, IL 60015 USA. Rev. April, 2011

What other drugs will affect Metronidazole (Mycogynax)?

Tell your doctor about all other medicines you use, especially:

  • cimetidine (Tagamet);

  • seizure medication such as phenytoin (Dilantin) or phenobarbital (Luminal, Solfoton);

  • a blood thinner such as warfarin (Coumadin, Jantoven);

  • lithium (Lithobid, Eskalith, others); or

  • disulfiram (Antabuse).

This list is not complete and other drugs may interact with Metronidazole (Mycogynax). Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Metronidazole (Mycogynax) interactions

infoInteractions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Metronidazole (Mycogynax), it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.

Oral Metronidazole (Mycogynax) has been reported to potentiate the anticoagulant effect of coumarin and warfarin resulting in a prolongation of prothrombin time. Drug interactions should be kept in mind when Metronidazole (Mycogynax) (Metronidazole (Mycogynax)) is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical Metronidazole (Mycogynax) administration because of low absorption.

Carcinogenesis, Mutagenesis and Impairment of Fertility: Metronidazole (Mycogynax) has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats but not in studies involving hamsters. In several long term studies in mice, oral doses of approximately 225 mg/m2/day or greater (approximately 37 times the human topical dose on a mg/m2 basis) were associated with an increase in pulmonary tumors and lymphomas. Several long term oral studies in the rat have shown statistically significant increases in mammary and hepatic tumors at doses >885 mg/m2/day (144 times the topical human dose).

Metronidazole (Mycogynax) has shown evidence of mutagenic activity in several in vitro bacterial assay systems. In addition, a dose-related increase in the frequency of micronuclei was observed in mice after intraperitoneal injections. An increase in chromosomal aberrations in peripheral blood lymphocytes was reported in patients with Crohn's disease who were treated with 200 to 1200 mg/day of Metronidazole (Mycogynax) for 1 to 24 months. However, in another study, no increase in chromosomal aberrations in circulating lymphocytes was observed in patients with Crohn's disease treated with the drug for 8 months.

In one published study, using albino hairless mice, intraperitoneal administration of Metronidazole (Mycogynax) at a dose of 45 mg/m2/day (approximately 7 times the human topical dose on a mg/m2 basis) was associated with an increase in ultraviolet radiation-induced skin carcinogenesis. Neither dermal carcinogenicity nor photocarcinogenicity studies have been performed with Metronidazole (Mycogynax) or any marketed Metronidazole (Mycogynax) formulations.

Pregnancy: Teratogenic Effects: Pregnancy Category B. There are no adequate and well controlled studies with the use of Metronidazole (Mycogynax) (Metronidazole (Mycogynax)) in pregnant women. Metronidazole (Mycogynax) crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral administration of Metronidazole (Mycogynax) to rats or mice at 200 and 20 times, respectively, the expected clinical dose. However, oral Metronidazole (Mycogynax) has shown carcinogenic activity in rodents. Because animal reproduction studies are not always predictive of human response, Metronidazole (Mycogynax) (Metronidazole (Mycogynax)) should be used during pregnancy only if clearly needed. Nursing Mothers: After oral administration, Metronidazole (Mycogynax) is secreted in breast milk in concentrations similar to those found in the plasma. Even though blood levels taken after topical Metronidazole (Mycogynax) application are significantly lower than those achieved after oral Metronidazole (Mycogynax), a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother and the risk to the infant.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Dosage of Nystatin (Mycogynax) in details

infoThe dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.

Usual Adult Dose for Cutaneous Candidiasis

Apply Nystatin (Mycogynax) topical cream, ointment or powder in a quantity sufficient to cover the affected area and immediately surrounding skin 2 to 4 times a day.

The powder formulation is useful for the treatment of moist areas or lesions.

Therapy should be continued for 2 to 8 weeks, depending on the nature and severity of the infection.

Usual Adult Dose for Vaginal Candidiasis

Insert one Nystatin (Mycogynax) vaginal tablet (100,000 units) vaginally once a day, preferably at bedtime, for a total of 14 days.

Usual Pediatric Dose for Cutaneous Candidiasis

Apply Nystatin (Mycogynax) topical cream, ointment or powder in a quantity sufficient to cover the affected area and immediately surrounding skin 2 to 4 times a day.

The powder formulation is useful for the treatment of moist areas or lesions.

Therapy should be continued for 2 to 8 weeks, depending on the nature and severity of the infection.

Usual Pediatric Dose for Vaginal Candidiasis

>13 <18 years: Insert one Nystatin (Mycogynax) vaginal tablet (100,000 units) vaginally once a day, preferably at bedtime, for a total of 14 days.

Other Comments

For fungal infections of the feet caused by Candida, dust the powder freely on the feet as well as in shoes and socks.

The vaginal tablets should be used continuously, regardless of initiation of menses.

For external use only. Avoid contact with the eyes.

What other drugs will affect Nystatin (Mycogynax)?

It is not likely that other drugs you take orally or inject will have an effect on topically applied Nystatin (Mycogynax) topical. But many drugs can interact with each other. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Nystatin (Mycogynax) interactions

infoInteractions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Nystatin (Mycogynax), it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.

Your healthcare professionals (e.g., doctor or pharmacist) may already be aware of any possible drug interactions and may be monitoring you for it. Do not start, stop or change the dosage of any medicine before checking with them first.

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use.

Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

References

  1. DailyMed. "BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. DailyMed. "DEXAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  3. DailyMed. "CHLORAMPHENICOL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Mycogynax are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Mycogynax. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

3 consumers reported frequency of use

How frequently do I need to take Mycogynax?
It was reported by ndrugs.com website users that Mycogynax should ideally be taken Once in a day as the most common frequency of the Mycogynax. You should you adhere strictly to the instructions and guidelines provided by your doctor on how frequently this Mycogynax should be taken. Get another patient's view on how frequent the capsule should be used by clicking here.
Users%
Once in a day2
66.7%
Twice in a day1
33.3%


3 consumers reported doses

What doses of Mycogynax drug you have used?
The drug can be in various doses. Most anti-diabetic, anti-hypertensive drugs, pain killers, or antibiotics are in different low and high doses and prescribed by the doctors depending on the severity and demand of the condition suffered by the patient. In our reports, ndrugs.com website users used these doses of Mycogynax drug in following percentages. Very few drugs come in a fixed dose or a single dose. Common conditions, like fever, have almost the same doses, e.g., [acetaminophen, 500mg] of drug used by the patient, even though it is available in various doses.
Users%
501mg-1g1
33.3%
6-10mg1
33.3%
11-50mg1
33.3%


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 30 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2020 ndrugs.com All Rights Reserved